Natural Capsules Limited has informed the Exchange regarding a press release dated March 12, 2026, titled "Natural Biogenex and Fermbox Bio Enter Strategic Framework andManufacturing Agreements to Strengthen Fermentation-Based CDMOCapabilities".
NATCAPSUQ · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Natural Capsules Limited's material subsidiary, Natural Biogenex Private Limited (NBPL), has signed Framework and Contract Manufacturing Agreements with Fermbox Bio Private Limited to offer fermentation-based CDMO services. Fermbox will place advanced fermentation technology and equipment worth up to ₹60 crore at NBPL's facility in Tumkur, while NBPL will handle licensed manufacturing, quality assurance and regulatory compliance. The partnership aims to serve global biotech and biopharma clients with GMP-compliant manufacturing capacity. Management described it as a pivotal step in expanding into high-value bio-manufacturing CDMO services for pharma and industrial biotech segments. The collaboration also aligns with government catalysts like the BioE3 Policy and the RDI initiative supporting India's biomanufacturing ecosystem.
This is a positive development that diversifies the group into the high-growth fermentation-based CDMO space with a significant ₹60 crore capital deployment by the partner, potentially opening new revenue streams and enhancing long-term valuation. Short-term stock reaction may be modestly positive given the strategic nature, though execution and revenue traction from this collaboration will be key watchpoints for investors.